A Multicenter, Phase 1B, Open-Label Study to Determine the Safety and Activity of CC-292 in Combination With Lenalidomide in Subjects With Relapsed and /or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Phase of Trial: Phase I
Latest Information Update: 24 May 2019
At a glance
- Drugs Spebrutinib (Primary) ; Lenalidomide
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 21 May 2019 Status changed from active, no longer recruiting to completed.
- 01 Mar 2018 Planned End Date changed from 31 Mar 2019 to 30 Mar 2019.
- 01 Mar 2018 Planned primary completion date changed from 31 Mar 2019 to 30 Mar 2019.